244 related articles for article (PubMed ID: 36243325)
1. Chitosan nanoparticles for intranasal delivery of olmesartan medoxomil: Pharmacokinetic and pharmacodynamic perspectives.
Hassan RH; Gad HA; El-Din SB; Shaker DS; Ishak RAH
Int J Pharm; 2022 Nov; 628():122278. PubMed ID: 36243325
[TBL] [Abstract][Full Text] [Related]
2. Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment.
Albash R; El-Nabarawi MA; Refai H; Abdelbary AA
Int J Nanomedicine; 2019; 14():6555-6574. PubMed ID: 31616143
[TBL] [Abstract][Full Text] [Related]
3. In Vitro and In Vivo Evaluation of Olmesartan Medoxomil Microcrysta ls and Nanocrystals: Preparation, Characterization, and Pharmacokinet ic Comparison in Beagle Dogs.
Chai R; Gao H; Ma Z; Guo M; Fu Q; Liu H; He Z
Curr Drug Deliv; 2019; 16(6):500-510. PubMed ID: 31244438
[TBL] [Abstract][Full Text] [Related]
4. Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation.
Nooli M; Chella N; Kulhari H; Shastri NR; Sistla R
Drug Dev Ind Pharm; 2017 Apr; 43(4):611-617. PubMed ID: 28005442
[TBL] [Abstract][Full Text] [Related]
5. Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability.
Kaithwas V; Dora CP; Kushwah V; Jain S
Colloids Surf B Biointerfaces; 2017 Jun; 154():10-20. PubMed ID: 28284054
[TBL] [Abstract][Full Text] [Related]
6. Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery.
Rukmangathen R; Yallamalli IM; Yalavarthi PR
Drug Dev Ind Pharm; 2019 Aug; 45(8):1342-1350. PubMed ID: 31094571
[No Abstract] [Full Text] [Related]
7. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment.
Bagre AP; Jain K; Jain NK
Int J Pharm; 2013 Nov; 456(1):31-40. PubMed ID: 23994363
[TBL] [Abstract][Full Text] [Related]
8. Development, optimisation and evaluation of chitosan nanoparticles of alendronate against Alzheimer's disease in intracerebroventricular streptozotocin model for brain delivery.
Zameer S; Ali J; Vohora D; Najmi AK; Akhtar M
J Drug Target; 2021 Feb; 29(2):199-216. PubMed ID: 32876502
[TBL] [Abstract][Full Text] [Related]
9. Optimization and Appraisal of Chitosan-Grafted PLGA Nanoparticles for Boosting Pharmacokinetic and Pharmacodynamic Effect of Duloxetine HCl Using Box-Benkhen Design.
Salem HF; Ali AA; Rabea YK; Abo El-Ela FI; Khallaf RA
J Pharm Sci; 2023 Feb; 112(2):544-561. PubMed ID: 36063878
[TBL] [Abstract][Full Text] [Related]
10. Development and Optimization of Chitosan Nanoparticle-Based Intranasal Vaccine Carrier.
Gao X; Liu N; Wang Z; Gao J; Zhang H; Li M; Du Y; Gao X; Zheng A
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011436
[TBL] [Abstract][Full Text] [Related]
11. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting.
Wang X; Chi N; Tang X
Eur J Pharm Biopharm; 2008 Nov; 70(3):735-40. PubMed ID: 18684400
[TBL] [Abstract][Full Text] [Related]
12. Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization.
Shahnaz G; Vetter A; Barthelmes J; Rahmat D; Laffleur F; Iqbal J; Perera G; Schlocker W; Dünnhaput S; Augustijns P; Bernkop-Schnürch A
Int J Pharm; 2012 May; 428(1-2):164-70. PubMed ID: 22421322
[TBL] [Abstract][Full Text] [Related]
13. Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis.
Saini D; Fazil M; Ali MM; Baboota S; Ali J
Drug Deliv; 2015; 22(6):823-36. PubMed ID: 24725026
[TBL] [Abstract][Full Text] [Related]
14. Use of transethosomes for enhancing the transdermal delivery of olmesartan medoxomil: in vitro, ex vivo, and in vivo evaluation.
Albash R; Abdelbary AA; Refai H; El-Nabarawi MA
Int J Nanomedicine; 2019; 14():1953-1968. PubMed ID: 30936696
[TBL] [Abstract][Full Text] [Related]
15. Intranasal delivery of tapentadol hydrochloride-loaded chitosan nanoparticles: formulation, characterisation and its in vivo evaluation.
Javia A; Thakkar H
J Microencapsul; 2017 Nov; 34(7):644-658. PubMed ID: 28862072
[TBL] [Abstract][Full Text] [Related]
16. Development and optimization of in-situ gel containing chitosan nanoparticles for possible nose-to-brain delivery of vinpocetine.
Hard SAAA; Shivakumar HN; Redhwan MAM
Int J Biol Macromol; 2023 Dec; 253(Pt 6):127217. PubMed ID: 37793522
[TBL] [Abstract][Full Text] [Related]
17. Formulation, optimization, and in vitro-in vivo evaluation of olmesartan medoxomil nanocrystals.
Jain S; Patel K; Arora S; Reddy VA; Dora CP
Drug Deliv Transl Res; 2017 Apr; 7(2):292-303. PubMed ID: 28116656
[TBL] [Abstract][Full Text] [Related]
18. Intranasal administration of brain-targeted HP-β-CD/chitosan nanoparticles for delivery of scutellarin, a compound with protective effect in cerebral ischaemia.
Liu S; Ho PC
J Pharm Pharmacol; 2017 Nov; 69(11):1495-1501. PubMed ID: 28809432
[TBL] [Abstract][Full Text] [Related]
19. Mucopenetrating nanoparticles for enhancement of oral bioavailability of furosemide: In vitro and in vivo evaluation/sub-acute toxicity study.
Radwan SE; Sokar MS; Abdelmonsif DA; El-Kamel AH
Int J Pharm; 2017 Jun; 526(1-2):366-379. PubMed ID: 28487189
[TBL] [Abstract][Full Text] [Related]
20. Intranasal Piperine-Loaded Chitosan Nanoparticles as Brain-Targeted Therapy in Alzheimer's Disease: Optimization, Biological Efficacy, and Potential Toxicity.
Elnaggar YS; Etman SM; Abdelmonsif DA; Abdallah OY
J Pharm Sci; 2015 Oct; 104(10):3544-56. PubMed ID: 26147711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
